Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BMEA |
---|---|---|
09:32 ET | 21915 | 5.09 |
09:34 ET | 7594 | 5.04 |
09:36 ET | 11368 | 4.93 |
09:38 ET | 14969 | 5.005 |
09:39 ET | 4275 | 5.045 |
09:41 ET | 8370 | 4.95 |
09:43 ET | 1772 | 4.9699 |
09:45 ET | 13933 | 4.9492 |
09:48 ET | 4909 | 4.95 |
09:50 ET | 402 | 4.95 |
09:52 ET | 8901 | 4.9 |
09:54 ET | 40790 | 4.83 |
09:56 ET | 19145 | 4.82 |
09:57 ET | 5327 | 4.87 |
09:59 ET | 5944 | 4.89 |
10:01 ET | 1104 | 4.92 |
10:03 ET | 9191 | 4.95 |
10:06 ET | 4939 | 4.93 |
10:08 ET | 557 | 4.91 |
10:10 ET | 101 | 4.9 |
10:12 ET | 60610 | 4.8613 |
10:14 ET | 990 | 4.84 |
10:15 ET | 3362 | 4.83 |
10:17 ET | 22629 | 4.8899 |
10:19 ET | 100 | 4.86 |
10:21 ET | 828 | 4.84 |
10:24 ET | 11079 | 4.82 |
10:26 ET | 2424 | 4.83 |
10:28 ET | 1195 | 4.84 |
10:30 ET | 24459 | 4.82 |
10:32 ET | 3016 | 4.83 |
10:33 ET | 6314 | 4.8188 |
10:35 ET | 9763 | 4.83 |
10:37 ET | 6086 | 4.7923 |
10:39 ET | 8795 | 4.755 |
10:42 ET | 4389 | 4.72 |
10:44 ET | 3919 | 4.725 |
10:46 ET | 6636 | 4.73 |
10:48 ET | 3056 | 4.74 |
10:51 ET | 16599 | 4.69 |
10:53 ET | 30423 | 4.7399 |
10:55 ET | 2974 | 4.74 |
10:57 ET | 6870 | 4.705 |
11:00 ET | 5110 | 4.7 |
11:02 ET | 7645 | 4.71 |
11:04 ET | 200 | 4.71 |
11:06 ET | 3031 | 4.71 |
11:08 ET | 1950 | 4.705 |
11:09 ET | 1049 | 4.705 |
11:11 ET | 5466 | 4.71 |
11:13 ET | 100 | 4.7 |
11:15 ET | 5591 | 4.68 |
11:18 ET | 4916 | 4.69 |
11:22 ET | 5449 | 4.6988 |
11:24 ET | 10562 | 4.7082 |
11:26 ET | 12085 | 4.715 |
11:27 ET | 5023 | 4.695 |
11:29 ET | 500 | 4.69 |
11:31 ET | 803 | 4.6903 |
11:33 ET | 6247 | 4.66 |
11:36 ET | 3278 | 4.655 |
11:38 ET | 10267 | 4.66 |
11:40 ET | 211 | 4.6417 |
11:42 ET | 8328 | 4.64 |
11:44 ET | 1492 | 4.625 |
11:45 ET | 5802 | 4.625 |
11:47 ET | 28262 | 4.62 |
11:49 ET | 3430 | 4.625 |
11:51 ET | 3690 | 4.635 |
11:54 ET | 9480 | 4.61 |
11:56 ET | 17940 | 4.635 |
11:58 ET | 5191 | 4.6683 |
12:00 ET | 1596 | 4.65 |
12:02 ET | 3238 | 4.61 |
12:03 ET | 3196 | 4.62 |
12:05 ET | 4931 | 4.66 |
12:07 ET | 1635 | 4.66 |
12:09 ET | 540 | 4.64 |
12:12 ET | 3894 | 4.6489 |
12:14 ET | 1100 | 4.63 |
12:16 ET | 944 | 4.63 |
12:18 ET | 2263 | 4.63 |
12:20 ET | 300 | 4.625 |
12:21 ET | 1506 | 4.62 |
12:23 ET | 1068 | 4.615 |
12:25 ET | 3961 | 4.61 |
12:27 ET | 1352 | 4.61 |
12:30 ET | 13455 | 4.6499 |
12:32 ET | 750 | 4.6388 |
12:34 ET | 2580 | 4.63 |
12:36 ET | 400 | 4.625 |
12:38 ET | 800 | 4.62 |
12:39 ET | 6635 | 4.64 |
12:41 ET | 100 | 4.63 |
12:43 ET | 3581 | 4.64 |
12:45 ET | 1000 | 4.63 |
12:48 ET | 1510 | 4.64 |
12:50 ET | 700 | 4.63 |
12:52 ET | 1493 | 4.645 |
12:54 ET | 1493 | 4.67 |
12:56 ET | 4035 | 4.67 |
12:57 ET | 3575 | 4.665 |
12:59 ET | 100 | 4.65 |
01:01 ET | 1300 | 4.6699 |
01:03 ET | 2356 | 4.68 |
01:06 ET | 3824 | 4.68 |
01:08 ET | 180 | 4.675 |
01:10 ET | 11195 | 4.66 |
01:12 ET | 500 | 4.655 |
01:14 ET | 4038 | 4.66 |
01:15 ET | 9077 | 4.64 |
01:17 ET | 5300 | 4.635 |
01:19 ET | 3374 | 4.62 |
01:21 ET | 2403 | 4.61 |
01:24 ET | 12671 | 4.605 |
01:26 ET | 5323 | 4.61 |
01:28 ET | 2065 | 4.615 |
01:30 ET | 3600 | 4.61 |
01:32 ET | 9059 | 4.6 |
01:33 ET | 5724 | 4.615 |
01:35 ET | 300 | 4.61 |
01:37 ET | 4399 | 4.62 |
01:39 ET | 2380 | 4.6 |
01:42 ET | 10017 | 4.59 |
01:44 ET | 8618 | 4.57 |
01:46 ET | 600 | 4.57 |
01:48 ET | 850 | 4.57 |
01:50 ET | 3367 | 4.565 |
01:51 ET | 2519 | 4.55 |
01:53 ET | 1400 | 4.55 |
01:55 ET | 8478 | 4.56 |
01:57 ET | 2499 | 4.565 |
02:00 ET | 2582 | 4.57 |
02:04 ET | 1188 | 4.55 |
02:06 ET | 700 | 4.555 |
02:08 ET | 5124 | 4.5583 |
02:09 ET | 17883 | 4.56 |
02:11 ET | 14609 | 4.5699 |
02:13 ET | 2967 | 4.575 |
02:15 ET | 2437 | 4.565 |
02:18 ET | 2290 | 4.56 |
02:20 ET | 7576 | 4.57 |
02:22 ET | 1684 | 4.57 |
02:24 ET | 945 | 4.57 |
02:26 ET | 3038 | 4.57 |
02:27 ET | 2932 | 4.555 |
02:29 ET | 420 | 4.558 |
02:31 ET | 719 | 4.55 |
02:33 ET | 4860 | 4.53 |
02:36 ET | 650 | 4.53 |
02:38 ET | 4311 | 4.54 |
02:40 ET | 1377 | 4.53 |
02:44 ET | 1928 | 4.53 |
02:45 ET | 2000 | 4.5398 |
02:47 ET | 700 | 4.53 |
02:49 ET | 1700 | 4.525 |
02:51 ET | 9864 | 4.51 |
02:54 ET | 15401 | 4.49 |
02:56 ET | 11501 | 4.505 |
02:58 ET | 1924 | 4.495 |
03:00 ET | 4920 | 4.4901 |
03:02 ET | 1500 | 4.47 |
03:03 ET | 1400 | 4.47 |
03:05 ET | 8691 | 4.46 |
03:07 ET | 5450 | 4.46 |
03:09 ET | 8684 | 4.4599 |
03:12 ET | 1419 | 4.455 |
03:14 ET | 144 | 4.4501 |
03:16 ET | 9947 | 4.42 |
03:18 ET | 1500 | 4.4201 |
03:20 ET | 26454 | 4.41 |
03:21 ET | 4675 | 4.405 |
03:23 ET | 200 | 4.405 |
03:25 ET | 4805 | 4.4 |
03:27 ET | 4183 | 4.405 |
03:30 ET | 1250 | 4.3998 |
03:32 ET | 1536 | 4.385 |
03:34 ET | 10668 | 4.39 |
03:36 ET | 9311 | 4.395 |
03:38 ET | 2296 | 4.3801 |
03:39 ET | 5816 | 4.375 |
03:41 ET | 17451 | 4.375 |
03:43 ET | 8834 | 4.3699 |
03:45 ET | 11689 | 4.375 |
03:48 ET | 22855 | 4.425 |
03:50 ET | 9356 | 4.425 |
03:52 ET | 2358 | 4.425 |
03:54 ET | 26183 | 4.44 |
03:56 ET | 6638 | 4.4301 |
03:57 ET | 21819 | 4.415 |
03:59 ET | 68972 | 4.45 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Biomea Fusion Inc | 187.3M | -1.2x | --- |
Acrivon Therapeutics Inc | 187.1M | -2.0x | --- |
Design Therapeutics Inc | 187.0M | -3.1x | --- |
Rani Therapeutics Holdings Inc | 188.6M | -3.0x | --- |
Trevi Therapeutics Inc | 183.8M | -7.9x | --- |
Pyxis Oncology Inc | 180.2M | -2.3x | --- |
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $187.3M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 35.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.57 |
Book Value | $4.72 |
P/E Ratio | -1.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.